UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials

Expert review of vaccines, 2018-12, Vol.17 (12), p.1085-1091

2018

Volltextzugriff (PDF)

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination

Human vaccines & immunotherapeutics, 2014-08, Vol.10 (8), p.2147-2162

2014

Volltextzugriff (PDF)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from Months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

Human vaccines, 2011-12, Vol.7 (12), p.1343-1358

2011

Volltextzugriff (PDF)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule

Human vaccines & immunotherapeutics, 2017-05, Vol.13 (5), p.1158-1166

2017

Volltextzugriff (PDF)

Design and evaluation of a multi-epitope DNA vaccine against HPV16

Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2352908-2352908

2024

Volltextzugriff (PDF)

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

Human vaccines & immunotherapeutics, 2016-01, Vol.12 (1), p.20-29

2016

Volltextzugriff (PDF)

Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention

Expert review of vaccines, 2018-12, Vol.17 (12), p.1093-1104

2018

Volltextzugriff (PDF)

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study

Human vaccines & immunotherapeutics, 2014, Vol.10 (5), p.1155-1165

2014

Volltextzugriff (PDF)

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

Expert review of vaccines, 2016-03, Vol.15 (3), p.367-387

2016

Volltextzugriff (PDF)

Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction

Human vaccines & immunotherapeutics, 2019-08, Vol.15 (7-8), p.1962-1969

2019

Volltextzugriff (PDF)

Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada

Human vaccines & immunotherapeutics, 2018-01, Vol.14 (1), p.118-123

2018

Volltextzugriff (PDF)

Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review

Expert review of vaccines, 2018-05, Vol.17 (5), p.395-409

2018

Volltextzugriff (PDF)

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Human vaccines & immunotherapeutics, 2019-08, Vol.15 (7-8), p.1970-1979

2019

Volltextzugriff (PDF)

Sex differences in HPV immunity among adults without cancer

Human vaccines & immunotherapeutics, 2019-08, Vol.15 (7-8), p.1935-1941

2019

Volltextzugriff (PDF)

Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types

Expert review of vaccines, 2012-06, Vol.11 (6), p.645-657

Szarewski, Anne

2012

Volltextzugriff (PDF)

Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

Human vaccines, 2011-02, Vol.7 (2), p.161-169

Romanowski, Barbara

2011

Volltextzugriff (PDF)

Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis

Expert review of vaccines, 2014-11, Vol.13 (11), p.1387-1393

2014

Volltextzugriff (PDF)

Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine

Expert review of vaccines, 2014-11, Vol.13 (11), p.1297-1306

2014

Volltextzugriff (PDF)

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial

Human vaccines & immunotherapeutics, 2013-07, Vol.9 (7), p.1399-1406

2013

Volltextzugriff (PDF)

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

Human vaccines, 2008-11, Vol.4 (6), p.425-434

2008

Volltextzugriff (PDF)

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults

Human vaccines, 2011-07, Vol.7 (7), p.768-775

2011

Volltextzugriff (PDF)

Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

Expert opinion on biological therapy, 2014-04, Vol.14 (4), p.527-534

2014

Volltextzugriff (PDF)

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

Human vaccines, 2011-09, Vol.7 (9), p.958-965

2011

Volltextzugriff (PDF)

Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model

Immunotherapy, 2012-11, Vol.4 (11), p.1107-1120

2012

Volltextzugriff (PDF)

Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: An approach for a capsomere-based HPV vaccine

Human vaccines & immunotherapeutics, 2014-10, Vol.10 (10), p.2975-2982

2014

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(118)

Sprache

Englisch
(118)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from Months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule

Design and evaluation of a multi-epitope DNA vaccine against HPV16

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study

Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases

Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction

Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada

Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years

Sex differences in HPV immunity among adults without cancer

Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types

Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines

Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis

Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial

Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine

Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults

Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years

Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model

Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: An approach for a capsomere-based HPV vaccine

Aktive Filter

Suchergebnisse filtern